Evidence map›Paper›PMID 40739045›Full record

ArticleBritish journal of cancer2025

Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.

Ying Ge, Meimei Yu, Tianjing Chang, Zixuan Wang, Yang Zhang, Hongyan Chen, Xuzhu Chen, Xin Li, Nan Ji, Huicong Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying Ge *Department of radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0009-0000-2692-3338
Meimei Yu *Department of radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-5488-8012
Tianjing ChangDepartment of Radiology, Shougang Hospital, Peking University, Beijing, China.
Zixuan WangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang ZhangDepartment of neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hongyan ChenDepartment of radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuzhu ChenDepartment of radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xin LiState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0009-0001-7493-8603
Nan JiDepartment of neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-9001-8858
Huicong ShenDepartment of radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. shenhuicong@126.com.ORCID http://orcid.org/0000-0002-9296-6915

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81772005
6 · The paper itself

Abstract

backgroundThe role of 2-hydroxyglutarate (2HG) in the methylation process of O6-methylguanine-DNA methyltransferase (MGMT) promoter remains unclear. This study aimed to investigate the predictive efficacy and role of 2HG in MGMT promoter methylation.

methodsPatients who met the inclusion criteria were retrospectively included and divided into MGMT promoter methylation group (M) and MGMT promoter unmethylation group (UM). 2HG, Glutamate (Glu), N-acetylaspartate (NAA), Choline (Cho), 2HG/Creatine (Cr), 2HG/Glu and Cho/NAA were calculated. Intergroup differences were estimated using Mann-Whitney U test and Chi-square test. Subsequently, the receiver operating characteristic (ROC) curves were plotted for evaluating diagnostic efficacy of metabolic indices with statistical differences. Then, the causal steps approach was performed for discussing the mediation effect of 2HG.

results75 patients (male: 52, female: 23, age: 46.81 ± 1.52 years) were included (48 in M, 27 in UM). Compared with UM, M exhibited higher 2HG, 2HG/Cr, 2HG/Glu, Cho/NAA and lower Glu, the differences were statistically significant (P < 0.05). 2HG/Glu exhibited the best diagnostic efficacy (area under curve: 0.788, [95%CI: 0.679-0.879]). 2HG is a mediator in the process of MGMT promoter methylation.

conclusions2HG/Glu exhibited the best efficacy in predicting MGMT promoter methylation, and 2HG is a mediator in the methylation process of MGMT promoter.

Indexed as

Brain NeoplasmsDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGliomaGlutaratesPromoter Regions, GeneticTumor Suppressor ProteinsAdultAspartic AcidFemaleHumansMagnetic Resonance SpectroscopyMaleMiddle AgedRetrospective Studiesalpha-hydroxyglutarateAspartic AcidDNA Modification MethylasesDNA Repair EnzymesGlutaratesMGMT protein, humanN-acetylaspartateTumor Suppressor Proteins

Identifiers

PMID40739045
PMCPMC12480185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.